Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...
Ancient evidence suggests a new twist in how we all got here.
Adds potential first-in-class,N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Equity Insider News Commentary, The scramble to build a critical-minerals supply chain outside China has become one of the ...
Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis.
In a world where "commercialization and criminalization are happening simultaneously," Prof. Kojo Koram explores the ...
Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results